SOX2 and endometrial cancer: Furthermore, high SOX2 accompanied by low p21 expressions in the patients of advanced endometrial cancer were associated with the most unfavorable outcomes, which indicated that the expression of SOX2 and p21 may be a useful biomarker for disease prognosis in endometrial cancer patients [29].